Biovica continues to increase 12m rolling IVD test sales in Q1 of SEK 0.93m (167% rolling 12m) and total net sales of SEK 2.6m after adding ROU & Pharma sales (test and services). Biovica is also progressing with a guaranteed rights issue at SEK 80m plus a SEK 42.2m Direct Share Issue (gross) and advancing the sales outlook based on Tempus AI in the Oncology segment, with a major partner in the IDN segment.
LÄS MER
